- Telix agreed to merge with ITM, the world's leading supplier of therapeutic radioisotopes and the only producer of globally scaled commercial-grade lutetium-177, creating a vertically integrated radiopharmaceutical company spanning development, isotope production and global manufacturing.
- Upfront consideration is US$1.65 billion cash-free/debt-free; after adjustments ITM shareholders receive about US$1.25 billion in Telix shares at US$11.84 each as Nasdaq ADRs, plus up to US$700 million contingent on ITM-11 regulatory and sales milestones.
- ITM posted US$273 million of revenue in 2025 with a 40% CAGR from 2021 to 2025, distributes across more than 65 countries, and its isotope manufacturing business is profitable and cash generative; the combined company is expected to show unaudited pro forma 2026 revenue and income above US$1.3 billion.
- ITM's pipeline includes ITM-11 (177Lu-edotreotide) for gastroenteropancreatic neuroendocrine tumors, which completed a successful Phase 3 COMPETE trial and fully enrolled the COMPOSE expansion study, with interim analysis expected in H1 2027.
- Management expects continued manufacturing growth, cost savings and pipeline synergies to support a positive EBITDA contribution in 2027, with an approved ITM-11 launch adding high-margin therapeutic revenue.
Quotes
“This merger positions Telix at the forefront of the consolidation that is occurring as the industry matures. ITM is the leader in radioisotope production, with deep scientific expertise and a track record of value-adding innovation.”